Cribriform and intraductal prostate cancer are both associated with an adverse outcome after radical prostatectomy. We included all patients with prostate cancer from the first screening round of the European Randomized Study of Screening for Prostate Cancer (ERSPC). All available slides were revised and scored for presence of cribriform and/or intraductal prostate cancer. Outcome measurements were biochemical recurrence and disease-specific survival. In total, 486 patients had Gleason score (GS) 6 (47%) and 545 GS ≥7 (53%). The disease-specific survival and biochemical-recurrence-free survival of CR/IDC−-GS3+4 patients did not differ significantly from those with GS 6, while patients with CR/IDC+-GS3+4-patients had a significant poorer outcome. Conclusion: The presence of cribriform and intraductal growth in prostate cancer, is a strong clinical prognostic marker with potential. The use of this variable in a clinical setting could contribute to reducing overtreatment of prostate cancer.

, ,,
Tijdschrift voor Urologie
Department of Pathology

Kweldam, C., Kümmerlin, I.P. (Intan P.), Nieboer, D., Verhoef, E., Steyerberg, E., Incrocci, L., … Leenders, G. (2017). De klinische relevantie van cribriforme en intraductale prostaatkanker in diagnostische naaldbiopten. Tijdschrift voor Urologie, 7(8), 168–177. doi:10.1007/s13629-016-0163-y